The current gold standard treatment for esophageal cancer is adjuvant chemoradiotherapy followed by surgical resection (Vrána et al., 2018), but a low immune response rate and drug resistance are unsolved to PD-L1 blockade. The gene discussed is CD274; the disease is esophageal cancer.